In the majority of SCLC with low SLFN11 expression, resistance to PARP inhibition may be overcome by pharmacologic ATR inhibition [37], further supporting the role for DDR synthetic lethality in enhancing response to PARP inhibitors in SCLC. Here, ATR is linked to small cell lung carcinoma.